EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Radium-223 treatment outcomes in patients with metastatic castration-resistant prostate cancer: A Taiwan-Japan collaborative cohort study

Hao Lun Luo, Yi Yang Liu, Hui Ying Liu, Yu Li Su, Yen-Hao Chen, Chikara Ohyama, Shingo Hatakeyama, Hideo Kawaguch, Masahiko Aoki, Yen-Hsiang Chang, Hung-Jen Wang, Yen Ta Chen und 2 weitere

Biomedical Journal · 2026-12 · 49 (6) · 100976

DOI: 10.1016/j.bj.2026.100976 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Biomedical Journal, 2026-12. Verfasst von Hao Lun Luo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chang Gung Memorial Hospital, Chang Gung Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This study examined oncologic outcomes associated with Radium-223 (Ra-223) administered at different treatment lines in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases, and evaluated the prognostic implications of biomarker responses-particularly prostate-specific antigen (PSA) and alkaline phosphatase (ALP)-during Ra-223 therapy. MATERIAL AND METHODS: Patients with mCRPC treated with Ra-223 between August 2016 and March 2023 were identified from the multi-institutional Chang Gung Research Database (Taiwan) and Hirosaki University Hospital (Aomori, Japan). The primary endpoint was the changes in biomarkers during Ra-223 treatment. Secondary endpoints included hematologic adverse events and survival outcomes. Multivariable Cox regression and sensitivity analyses were performed to adjust for baseline clinical factors and potential selection bias. RESULTS: Among 306 included patients, earlier use of Ra-223 was associated with more favorable biomarker dynamics, including smaller post-treatment PSA increase and greater ALP reductions (p = 0.003). Post-treatment PSA velocity was significantly lower, and post-Ra-223 survival was longer (both p < 0.001), particularly in patients with ALP decreases or PSA increases

Schlagwörter

Stichwörter der Autor:innen

Alkaline Phosphatase (ALP)BiomarkersMetastatic Castration-Resistant Prostate Cancer (mCRPC)Prostate-specific antigen (PSA)Radium-223 (Ra-223)Survival risk

Autor:innen und Institutionen

  • Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Department of Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Department of Urology, Hirosaki University Graduate of Medicine, Hirosaki, Japan.
  • Department of Urology, Hirosaki University Graduate of Medicine, Hirosaki, Japan; Department of Advanced Blood Purification Therapy, Hirosaki University Graduate of Medicine, Hirosaki, Japan.
  • Department of Radiation Oncology, Hirosaki University Graduate of Medicine, Hirosaki, Japan.
  • Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.

Förderung

  • Chang Gung Memorial Hospital
  • Chang Gung Medical Foundation

Zitieren

APA

Luo, H. L., Liu, Y. Y., Liu, H. Y., Su, Y. L., Chen, Y. H., Ohyama, C., Hatakeyama, S., Kawaguch, H., Aoki, M., Chang, Y. H., Wang, H. J., Chen, Y. T., Wu, Y. T., & Chang, Y. L. (2026). Radium-223 treatment outcomes in patients with metastatic castration-resistant prostate cancer: A Taiwan-Japan collaborative cohort study. Biomedical Journal, 49(6), 100976. https://doi.org/10.1016/j.bj.2026.100976

Vancouver

Luo HL, Liu YY, Liu HY, Su YL, Chen YH, Ohyama C, et al. Radium-223 treatment outcomes in patients with metastatic castration-resistant prostate cancer: A Taiwan-Japan collaborative cohort study. Biomedical Journal. 2026;49(6):100976. doi:10.1016/j.bj.2026.100976

BibTeX
@article{Luo2026,
  author = {Luo, Hao Lun and Liu, Yi Yang and Liu, Hui Ying and Su, Yu Li and Chen, Yen-Hao and Ohyama, Chikara and Hatakeyama, Shingo and Kawaguch, Hideo and Aoki, Masahiko and Chang, Yen-Hsiang and Wang, Hung-Jen and Chen, Yen Ta and Wu, Yen Ting and Chang, Yin Lun},
  title = {Radium-223 treatment outcomes in patients with metastatic castration-resistant prostate cancer: A Taiwan-Japan collaborative cohort study},
  journal = {Biomedical Journal},
  year = {2026},
  volume = {49},
  number = {6},
  pages = {100976},
  doi = {10.1016/j.bj.2026.100976}
}
Kostenlos starten →